EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 3.0

Astragaloside IV Co-Loaded Osimertinib Liposomes Alleviate EGFR-TKI Resistance in Non-Small Cell Lung Cancer

Mi Li, Yifei Tang, Yan He, Cui-Yu Xie, Jia-Rong Zhang, Zipeng Gong, Le-Le Zhang

International Journal of Nanomedicine · 2026-06 · Volume 21 · 1-19

DOI: 10.2147/ijn.s599341 ↗

Kurz gefasst

Fachartikel in der Zeitschrift International Journal of Nanomedicine, 2026-06. Verfasst von Mi Li und 6 weiteren Autor:innen. Beteiligte Einrichtung: College of Pharmacy, Chengdu University, Chengdu, Sichuan, People's Republic of China. Hauptthemen laut MEDLINE: Saponins, Carcinoma, Non-Small-Cell Lung, Triterpenes, Lung Neoplasms. Die Arbeit nennt 51 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 3.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

SaponinsCarcinoma, Non-Small-Cell LungTriterpenesLung NeoplasmsDrug Resistance, NeoplasmAniline CompoundsAcrylamidesProtein Kinase InhibitorsAntineoplastic AgentsHumansAnimalsCell Line, TumorLiposomesErbB ReceptorsIndolesPyrimidinesEpithelial-Mesenchymal TransitionMiceMice, NudeXenograft Model Antitumor AssaysMice, Inbred BALB CDrug LiberationCell ProliferationFemale

Stichwörter der Autor:innen

EGFR-TKINSCLCastragaloside IVdrug resistance

Substanzen

SaponinsTriterpenesastragaloside ALiposomesAniline CompoundsErbB ReceptorsosimertinibIndolesPyrimidinesAcrylamides

Autor:innen und Institutionen

  • College of Pharmacy, Chengdu University, Chengdu, Sichuan, People's Republic of China.
  • School of Preclinical Medicine, Chengdu University, Chengdu, Sichuan, People's Republic of China.
  • State Key Laboratory of Discovery and Utilization of Functional Components in Traditional Chinese Medicine, Guizhou Medical University, Guiyang, Guizhou, People's Republic of China.

Zitieren

APA

Li, M., Tang, Y., He, Y., Xie, C. Y., Zhang, J. R., Gong, Z., & Zhang, L. L. (2026). Astragaloside IV Co-Loaded Osimertinib Liposomes Alleviate EGFR-TKI Resistance in Non-Small Cell Lung Cancer. International Journal of Nanomedicine, Volume 21, 1-19. https://doi.org/10.2147/ijn.s599341

Vancouver

Li M, Tang Y, He Y, Xie CY, Zhang JR, Gong Z, et al. Astragaloside IV Co-Loaded Osimertinib Liposomes Alleviate EGFR-TKI Resistance in Non-Small Cell Lung Cancer. International Journal of Nanomedicine. 2026;Volume 21:1-19. doi:10.2147/ijn.s599341

BibTeX
@article{Li2026,
  author = {Li, Mi and Tang, Yifei and He, Yan and Xie, Cui-Yu and Zhang, Jia-Rong and Gong, Zipeng and Zhang, Le-Le},
  title = {Astragaloside IV Co-Loaded Osimertinib Liposomes Alleviate EGFR-TKI Resistance in Non-Small Cell Lung Cancer},
  journal = {International Journal of Nanomedicine},
  year = {2026},
  volume = {Volume 21},
  pages = {1--19},
  doi = {10.2147/ijn.s599341}
}
Kostenlos starten →